Robert J. Motzer

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

  UNC Libraries · 2025-12-19

• Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

  CA A Cancer Journal for Clinicians · 2025-12-13

• Pathologic Response to Immunotherapy Is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell Carcinoma

  European Urology Oncology · 2025-11-26 · 1 citations

• Supplementary Tables S1-S5 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade

  2025-11-25

• Supplementary Tables S6-S8 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade

  2025-11-25

• MLH1 Mismatch Repair Deficiency Predicts Exceptional Response to Immune Checkpoint Inhibition in Clear-cell Renal Cell Carcinoma

  European Urology · 2025-11-01

• Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial

  Annals of Oncology · 2025-10-18 · 8 citations

• Postimmunotherapy and Vascular Endothelial Growth Factor Inhibitor Landscape in Advanced Renal Cell Carcinoma: Treatment Patterns, Costs, and Outcomes

  JCO Oncology Practice · 2025-10-13 · 1 citations

• 46Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC)

  The Oncologist · 2025-10-01

• 44Overview of tivozanib (tivo) safety in phase 3 clinical trials in patients with metastatic renal cell carcinoma (mRCC)

  The Oncologist · 2025-10-01

• 22Final results of the phase 3 COSMIC-313 study comparing first-line cabozantinib plus nivolumab and ipilimumab with nivolumab plus ipilimumab in patients with advanced renal-cell carcinoma

  The Oncologist · 2025-10-01

• Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium

  The Lancet Oncology · 2025-10-01 · 8 citations

• 34Hypoxia and immune suppression shapes therapeutic outcomes and metastases in clear cell renal cell carcinoma

  The Oncologist · 2025-10-01

• Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial

  Annals of Oncology · 2025-09-24 · 18 citations

• Long-term oncologic outcomes of metastatic clear-cell renal cell carcinoma after local therapy alone

  Urologic Oncology Seminars and Original Investigations · 2025-09-11

• Defining the Histopathological, Clinical, and Genetic Characteristics of Familial BAP1-associated Renal Cell Carcinoma

  European Urology · 2025-09-08 · 2 citations

• Radiomic biomarkers associated with immune checkpoint blockade response for advanced renal cell carcinoma

  Urologic Oncology Seminars and Original Investigations · 2025-09-05

• 2594MO Association of circulating kidney injury molecule-1 (KIM-1) levels with clinical outcomes in advanced renal cell carcinoma (aRCC): Retrospective analysis of COSMIC-313

  Annals of Oncology · 2025-09-01 · 3 citations

• Biomarkers for renal cell carcinoma — a pragmatic approach

  Nature Reviews Urology · 2025-07-30 · 1 citations

• Dupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series

  The Oncologist · 2025-07-10 · 11 citations